Update on Biosimilars in Asia-Reference-Cited by-同舟云学术

Update on Biosimilars in Asia

Published:2017-07-17 Issue:8 Volume:19 Page:
ISSN:1523-3774
Container-title:Current Rheumatology Reports
language:en
Short-container-title:Curr Rheumatol Rep

Author:

Tsai Wen-Chan

Publisher

Springer Science and Business Media LLC

Subject

Rheumatology

Link

http://link.springer.com/article/10.1007/s11926-017-0677-1/fulltext.html

Reference31 articles.

1. Kim EY, Moudgil KD. Immunomodulation of autoimmune arthritis by pro-inflammatory cytokines. Cytokine. 2017; doi: 10.1016/j.cyto.2017.04.012 .

2. Schinnerling K, Aguillón JC, Catalán D, Soto L. The role of interleukin-6 signaling and its therapeutic blockage in skewing the T cell balance in rheumatoid arthritis. Clin Exp Immunol. 2017; doi: 10.1111/cei.12966 .

3. Scheinberg MA, Azevedo VF. Biosimilars in rheumatology: perspective and concerns. Rheumatology (Oxford). 2014;53(3):389–90.

4. Top 50 pharmaceutical products by global sales. http://www.pmlive.com/top_pharma_list/Top_50_pharmaceutical_products_by_global_sales (accessed 22/Apr/2017).

5. The brave new world of biosimilars. https://www.futurereadysingapore.com/2017/the-brave-new-world-of-biosimilars.html (accessed 22/Apr/2017).

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BOB: Bayesian optimal design for biosimilar trials with co‐primary endpoints;Statistics in Medicine;2022-09-20

2. The whole experience of public hospital physicians from several specialties with biopharmaceutical effectiveness, safety, adverse drug reactions and interchangeability: A qualitative study;Exploratory Research in Clinical and Social Pharmacy;2022-09

3. Rituximab biosimilars in hematologic malignancies: the need for a real-world approach;Future Oncology;2020-09

4. Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: An Overview;Biomedicines;2020-08-23

5. Global challenges in the manufacture, regulation and international harmonization of GMP and quality standards for biopharmaceuticals;Generics and Biosimilars Initiative Journal;2020-06-15